Ioannis Orfanidis

Biomechanical testing and material characterization for the rat large intestine: regional dependence of material parameters

D. Sokolis, Ioannis Orfanidis, M. Peroulis, 2011, Physiological measurement.

Effects of altered cellular ultrastructure on energy metabolism in diabetic cardiomyopathy: an in silico study

E. Hanssen, F. Spill, A. Hickey, 2022, bioRxiv.

Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial.

M. Dimopoulos, H. Einsele, P. Sonneveld, 2021, The Lancet. Oncology.

Apollo: Phase 3 Randomized Study of Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

M. Dimopoulos, H. Einsele, P. Sonneveld, 2020 .

Health‐related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient‐reported outcomes from the APOLLO trial

M. Dimopoulos, H. Einsele, P. Sonneveld, 2022, American journal of hematology.

Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Overall Survival Results from the Phase 3 Apollo Study

M. Dimopoulos, H. Einsele, P. Sonneveld, 2022, Blood.

Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial.

M. Boccadoro, A. Symeonidis, E. Katodritou, 2023, The Lancet. Haematology.